Prof. Linglong Tang 唐玲珑
Chief Physician, Professor
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for head and neck tumors, with a focus on intensity-modulated radiation therapy (IMRT) and comprehensive treatment for nasopharyngeal carcinoma.
Dr. Tang holds a bachelor's degree from Sun Yat-sen University of Medical Sciences (2002), and master's (2006) and doctoral (2015) degrees in oncology from Sun Yat-sen University Cancer Center. Dr. Tang served as Associate Chief Physician in the Department of Radiation Oncology from 2015 to 2019, and has been Chief Physician since 2020.
Professional roles
- Member, Nasopharyngeal Carcinoma Committee, China Anti-Cancer Association
- Member, Nasopharyngeal Carcinoma Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Nasopharyngeal Carcinoma Biomarker Committee, Tumor Marker Committee, China Anti-Cancer Association
- Member and Secretary, Radiation Therapy Branch, Guangdong Medical Association
Name order: in Chinese the family name comes first (Tang Linglong). Papers usually list the name as Linglong Tang or Tang L.
Selected publications
193 papers on PubMed matched by name and affiliation; 35 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Combined Real-time Liquid Biopsy With TNM Stage to Guide Induction Chemotherapy Cycles in Nasopharyngeal Carcinoma: A Development and Validation Study. PubMed 41831793
- Radiother Oncol, 2026 (senior author): Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy". [Radiother Oncol. 190 (2024) 109985]. PubMed 41702257
- Lancet Oncol, 2025 (first author): Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. PubMed 40907527
- Lancet Oncol, 2025 (first author): Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. PubMed 40907526
- CA Cancer J Clin, 2025 (first author): Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. PubMed 39970442
- Radiother Oncol, 2025 (senior author): Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy" [Radiother. Oncol. 190 (2024) 109985]. PubMed 39823926
- Radiother Oncol, 2024 (senior author): Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma. PubMed 39191301
- Adv Sci (Weinh), 2024 (senior author): DCAF7 Acts as A Scaffold to Recruit USP10 for G3BP1 Deubiquitylation and Facilitates Chemoresistance and Metastasis in Nasopharyngeal Carcinoma. PubMed 38973296
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion